Synaptogenix (NASDAQ:SNPX) Shares Down 5.6% – What’s Next?

Synaptogenix, Inc. (NASDAQ:SNPX)’s share price traded down 5.6% on Tuesday . The company traded as low as $2.82 and last traded at $2.84. 3,691 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 17,126 shares. The stock had previously closed at $3.01.

Synaptogenix Price Performance

The business has a fifty day simple moving average of $3.21 and a 200-day simple moving average of $3.19.

Hedge Funds Weigh In On Synaptogenix

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC bought a new position in shares of Synaptogenix, Inc. (NASDAQ:SNPX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned about 0.80% of Synaptogenix as of its most recent SEC filing. 10.34% of the stock is currently owned by institutional investors and hedge funds.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.